The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science
- PMID: 20407457
- DOI: 10.1038/clpt.2010.27
The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science
Abstract
Many successful large industries, such as computer-chip manufacturers, the cable television industry, and high-definition television developers,(1) have established successful precompetitive collaborations focusing on standards, applied science, and technology that advance the field for all stakeholders and benefit the public.(2) The pharmaceutical industry, however, has a well-earned reputation for fierce competition and did not demonstrate willingness to share data or knowledge until the US Food and Drug Administration (FDA) launched the Critical Path Initiative in 2004 (ref. 3).
Similar articles
-
How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.Clin Pharmacol Ther. 2010 May;87(5):614-6. doi: 10.1038/clpt.2010.21. Epub 2010 Apr 7. Clin Pharmacol Ther. 2010. PMID: 20376001 Review. No abstract available.
-
The critical path initiative: leveraging collaborations to enhance regulatory science.Clin Pharmacol Ther. 2012 Mar;91(3):380-3. doi: 10.1038/clpt.2011.318. Clin Pharmacol Ther. 2012. PMID: 22343813
-
Precompetitive research: a new prescription for drug development?Clin Pharmacol Ther. 2010 May;87(5):521-3. doi: 10.1038/clpt.2010.28. Clin Pharmacol Ther. 2010. PMID: 20407454 No abstract available.
-
Arguments against precompetitive collaboration.Clin Pharmacol Ther. 2010 May;87(5):527-9. doi: 10.1038/clpt.2010.30. Clin Pharmacol Ther. 2010. PMID: 20407456 Review. No abstract available.
-
Chutes and ladders on the critical path:comparative effectiveness, product value, and the use of biomarkers in drug development.Clin Pharmacol Ther. 2009 Jul;86(1):12-4. doi: 10.1038/clpt.2009.33. Clin Pharmacol Ther. 2009. PMID: 19536116 No abstract available.
Cited by
-
Data standards for model-informed drug development: an ISoP initiative.J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):659-661. doi: 10.1007/s10928-018-9595-8. Epub 2018 Jul 25. J Pharmacokinet Pharmacodyn. 2018. PMID: 30046963 No abstract available.
-
Drug Discovery in Academia- the third way?Expert Opin Drug Discov. 2010 Oct 1;5(10):909-19. doi: 10.1517/17460441.2010.506508. Expert Opin Drug Discov. 2010. PMID: 20922062 Free PMC article.
-
Where will the (New) Drugs for Traumatic Brain Injury Treatment be Coming From?Front Neurol. 2012 Mar 2;3:27. doi: 10.3389/fneur.2012.00027. eCollection 2012. Front Neurol. 2012. PMID: 22403571 Free PMC article. No abstract available.
-
Hypoxia-targeted drug delivery.Chem Soc Rev. 2019 Feb 4;48(3):771-813. doi: 10.1039/c8cs00304a. Chem Soc Rev. 2019. PMID: 30575832 Free PMC article. Review.
-
Food and Drug Administration perspective: Advancing product development for non-healing chronic wounds.Wound Repair Regen. 2022 May;30(3):299-302. doi: 10.1111/wrr.13008. Epub 2022 Apr 6. Wound Repair Regen. 2022. PMID: 35385594 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources